Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion type Assertion NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_head.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion description "[In the first patients with severe combined immunodeficiency due to adenosine deaminase deficiency treated with peripheral blood lymphocytes, transduced T cells have been shown to persist for over 10 years, expressing transgenic adenosine deaminase, but the therapeutic effect of gene therapy remained difficult to assess because of the concomitant treatment with bovine adenosine deaminase conjugated to polyethylene-glycol (PEG-ADA).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_provenance.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion evidence source_evidence_literature NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_provenance.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion SIO_000772 14612670 NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_provenance.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion wasDerivedFrom befree-20150227 NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_provenance.
- NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_assertion wasGeneratedBy ECO_0000203 NP605719.RAEBrtS6W5-ZWvnZqF_Ey2QLXL9eg0yBczmyYLYKkPlHo130_provenance.